Breaking News Instant updates and real-time market news.

GILD

Gilead

$77.99

0.77 (1.00%)

08:47
10/02/18
10/02
08:47
10/02/18
08:47

Kite, HiFiBiO announce research collaboration

Kite, a Gilead company, and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery of neoantigen-reactive T cell receptors, or TCRs, for the potential treatment of various cancers, including solid tumors. Kite and HiFiBiO intend to adapt HiFiBiO's proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies. Neoantigens arise from tumor-specific mutations that are unique to each patient's cancer, offering the potential for more targeted antitumor activity. Under the terms of the agreement, HiFiBiO will receive a $10 million upfront payment and will be eligible for additional payments based on the achievement of certain research milestones. Kite will have an exclusive option to license HiFiBiO's platform to screen T cell repertoires and to identify TCRs for use in TCR engineered T cell therapies with a corresponding payment to HiFiBiO.

  • 03

    Oct

GILD Gilead
$77.99

0.77 (1.00%)

09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
Diplomat Pharmacy weakness on Gilead generics overdone, says JPMorgan
JPMorgan analyst Lisa Gill says the weakness yesterday in shares of Diplomat Pharmacy (DPLO) following Gilead's (GILD) announcement that it will be launching new authorized generic versions of hepatitis C treatments Epclusa and Harvoni is a "significant overreaction." Hepatitis C represents a relatively small portion of revenue for Diplomat Pharmacy, and as such, these two drugs are not material, Gill tells investors in a research note. Further, the analyst believes it is unclear whether payors will adopt the authorized generic in lieu of continuing to receive rebates on the branded drugs. In addition, Gill thinks Diplomat should be able to purchase the new authorized generics at a discount to the new list price with a higher gross margin spread relative to the brand. The analyst keeps an Overweight rating on the shares.
09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.

TODAY'S FREE FLY STORIES

IPG

Interpublic Group

$22.48

0.28 (1.26%)

07:04
10/19/18
10/19
07:04
10/19/18
07:04
Earnings
Interpublic Group reports Q3 adj. EPS 48c, consensus 46c »

Reports Q3 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

IBKC

Iberiabank

$75.27

-2.65 (-3.40%)

07:04
10/19/18
10/19
07:04
10/19/18
07:04
Earnings
Breaking Earnings news story on Iberiabank »

Iberiabank reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

07:04
10/19/18
10/19
07:04
10/19/18
07:04
Earnings
Procter & Gamble reports Q1 core EPS $1.12, consensus $1.09 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 03

    Mar

SLB

Schlumberger

$58.43

-0.81 (-1.37%)

07:04
10/19/18
10/19
07:04
10/19/18
07:04
Earnings
Schlumberger reports Q3 EPS 46c, consensus 45c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RCI

Rogers Communications

$51.57

0.02 (0.04%)

07:02
10/19/18
10/19
07:02
10/19/18
07:02
Hot Stocks
Rogers Communications raises FY18 adj. EBITDA, free cash flow views »

Raises FY18 adj. EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORLY

O'Reilly Automotive

$338.38

3.31 (0.99%)

07:02
10/19/18
10/19
07:02
10/19/18
07:02
Upgrade
O'Reilly Automotive rating change  »

O'Reilly Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 29

    Oct

ETFC

E-Trade

$48.89

-1.68 (-3.32%)

07:00
10/19/18
10/19
07:00
10/19/18
07:00
Periodicals
E-Trade's board does not plan to initiate a sale, Reuters reports »

E-Trade's board does…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.57

0.02 (0.04%)

07:00
10/19/18
10/19
07:00
10/19/18
07:00
Earnings
Rogers Communications reports Q3 EPS C$1.21, consensus C$1.17 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$76.67

-1.15 (-1.48%)

06:59
10/19/18
10/19
06:59
10/19/18
06:59
Earnings
Sensient sees Q4 EPS down in mid-single digits y-o-y »

The company has a number…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

06:59
10/19/18
10/19
06:59
10/19/18
06:59
Hot Stocks
VF Corp. raises quarterly dividend 11% to 51c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DHT

DHT Holdings

$4.79

-0.17 (-3.43%)

06:58
10/19/18
10/19
06:58
10/19/18
06:58
Upgrade
DHT Holdings rating change  »

DHT Holdings upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

06:58
10/19/18
10/19
06:58
10/19/18
06:58
Earnings
VF Corp. raises FY19 adjusted EPS view to $3.65 from $3.52-$3.57 »

FY19 consensus $3.65.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

BMTC

Bryn Mawr Bank

$42.79

-1.86 (-4.17%)

06:58
10/19/18
10/19
06:58
10/19/18
06:58
Downgrade
Bryn Mawr Bank rating change  »

Bryn Mawr Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$76.67

-1.15 (-1.48%)

06:57
10/19/18
10/19
06:57
10/19/18
06:57
Earnings
Sensient reports Q3 adjusted EPS 95c, one estimate 95c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

THRM

Gentherm

$39.13

-0.76 (-1.91%)

06:57
10/19/18
10/19
06:57
10/19/18
06:57
Downgrade
Gentherm rating change  »

Gentherm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

06:57
10/19/18
10/19
06:57
10/19/18
06:57
Hot Stocks
Breaking Hot Stocks news story on VF Corp. »

VF Corp. raises FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

06:56
10/19/18
10/19
06:56
10/19/18
06:56
Earnings
VF Corp. reports Q2 adjusted EPS $1.43, consensus $1.33 »

Reports Q2 revenue $3.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DAN

Dana

$15.77

-0.67 (-4.08%)

06:55
10/19/18
10/19
06:55
10/19/18
06:55
Upgrade
Dana rating change  »

Dana upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 29

    Oct

UBER

Uber

$0.00

(0.00%)

06:49
10/19/18
10/19
06:49
10/19/18
06:49
Periodicals
Uber diversifies into short-term staffing business ahead of IPO, FT says »

In an effort to be seen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

, VLO

Valero

$103.31

-0.36 (-0.35%)

06:48
10/19/18
10/19
06:48
10/19/18
06:48
Downgrade
Valero Energy Partners, Valero rating change  »

Valero Energy Partners…

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

VLO

Valero

$103.31

-0.36 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 25

    Oct

IBKC

Iberiabank

$75.27

-2.65 (-3.40%)

06:48
10/19/18
10/19
06:48
10/19/18
06:48
Hot Stocks
Iberiabank increases quarterly dividend approximately 5% to 41c per share »

The board of Iberiabank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

STN

Stantec

$24.37

-0.2 (-0.81%)

06:48
10/19/18
10/19
06:48
10/19/18
06:48
Hot Stocks
Stantec to sell MWH Constructors »

Stantec has signed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

06:44
10/19/18
10/19
06:44
10/19/18
06:44
Upgrade
PayPal rating change  »

PayPal upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

TRV

Travelers

$125.08

-1.39 (-1.10%)

06:44
10/19/18
10/19
06:44
10/19/18
06:44
Downgrade
Travelers rating change  »

Travelers downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.51

-0.255 (-2.91%)

06:41
10/19/18
10/19
06:41
10/19/18
06:41
Downgrade
Ford rating change  »

Ford downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.